LEHI, Utah, May 28, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., The Genetic Resilience Company™, a clinical-stage biopharmaceutical company advancing first-in-class inflammation therapies anchored in protective human genetics, today announced that the Company will participate in the Jefferies 2026 Global Healthcare conference being held June 2-4, 2026, in New York City.
The Company will host one-on-one meetings with institutional investors on June 2, 2026. Investors interested in scheduling a meeting with Halia Therapeutics are encouraged to contact their Jefferies representative.
About Halia Therapeutics
Halia Therapeutics is a clinical-stage platform company focused on inflammation biology. The company's platform is anchored in protective human genetics that identified the LRRK2 -> RAB10 -> NEK7 -> NLRP3 axis as a source of human disease resilience. Halia is translating that biology into a pipeline of first-in-class programs, including HT-6184 in lower-risk myelodysplastic syndromes and additional hematologic indications, HT-4253 for Alzheimer's disease in APOE4 carriers, HT-6105 targeting residual inflammatory risk via hsCRP reduction, and HT-10068 for metabolic disease. To learn more, visit haliatx.com.
Contacts
Taylor Avei
Director of Business Development
Halia Therapeutics
tavei@haliatx.com
Investor Relations
Leigh Salvo
New Street Investor Relations
leigh@newstreetir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halia-therapeutics-to-participate-in-jefferies-2026-global-healthcare-conference-302784019.html
SOURCE Halia Therapeutics
